Garrison Point Advisors LLC Sells 600 Shares of Merck & Co., Inc. (NYSE:MRK)

by · The Markets Daily

Garrison Point Advisors LLC cut its holdings in Merck & Co., Inc. (NYSE:MRK – Free Report) by 8.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 6,208 shares of the company’s stock after selling 600 shares during the period. Garrison Point Advisors LLC’s holdings in Merck & Co., Inc. were worth $705,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of MRK. Industrial Alliance Investment Management Inc. lifted its holdings in shares of Merck & Co., Inc. by 2.6% during the 1st quarter. Industrial Alliance Investment Management Inc. now owns 3,193 shares of the company’s stock valued at $421,000 after buying an additional 80 shares during the period. IRON Financial LLC lifted its holdings in Merck & Co., Inc. by 4.6% in the second quarter. IRON Financial LLC now owns 1,811 shares of the company’s stock valued at $224,000 after acquiring an additional 80 shares during the period. Argent Capital Management LLC boosted its position in Merck & Co., Inc. by 0.8% in the second quarter. Argent Capital Management LLC now owns 10,521 shares of the company’s stock worth $1,302,000 after purchasing an additional 81 shares during the last quarter. Forza Wealth Management LLC grew its stake in shares of Merck & Co., Inc. by 0.8% during the 2nd quarter. Forza Wealth Management LLC now owns 10,480 shares of the company’s stock valued at $1,297,000 after purchasing an additional 82 shares during the period. Finally, Vista Investment Partners LLC increased its position in shares of Merck & Co., Inc. by 2.0% during the 2nd quarter. Vista Investment Partners LLC now owns 4,164 shares of the company’s stock valued at $516,000 after purchasing an additional 82 shares during the last quarter. 76.07% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts have recently weighed in on MRK shares. Barclays dropped their price target on shares of Merck & Co., Inc. from $142.00 to $140.00 and set an “overweight” rating on the stock in a research note on Monday, October 7th. Morgan Stanley raised their price objective on Merck & Co., Inc. from $132.00 to $134.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 11th. UBS Group cut their price objective on Merck & Co., Inc. from $142.00 to $136.00 and set a “buy” rating for the company in a research note on Wednesday, October 9th. Wells Fargo & Company reduced their target price on shares of Merck & Co., Inc. from $140.00 to $125.00 and set an “equal weight” rating for the company in a report on Wednesday, July 31st. Finally, Evercore ISI raised shares of Merck & Co., Inc. to a “strong-buy” rating in a report on Tuesday, July 30th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, nine have assigned a buy rating and four have given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $131.62.

Get Our Latest Research Report on MRK

Merck & Co., Inc. Stock Down 0.5 %

NYSE MRK opened at $105.88 on Friday. The stock has a 50 day moving average price of $113.86 and a 200-day moving average price of $121.93. Merck & Co., Inc. has a one year low of $99.80 and a one year high of $134.63. The company has a debt-to-equity ratio of 0.80, a quick ratio of 1.22 and a current ratio of 1.47. The company has a market capitalization of $268.17 billion, a P/E ratio of 19.64, a P/E/G ratio of 1.52 and a beta of 0.39.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last posted its earnings results on Tuesday, July 30th. The company reported $2.28 earnings per share for the quarter, topping analysts’ consensus estimates of $2.16 by $0.12. Merck & Co., Inc. had a net margin of 21.99% and a return on equity of 40.69%. The firm had revenue of $16.10 billion for the quarter, compared to the consensus estimate of $15.87 billion. During the same period in the previous year, the firm posted ($2.06) EPS. The business’s quarterly revenue was up 7.1% on a year-over-year basis. As a group, equities analysts predict that Merck & Co., Inc. will post 7.8 EPS for the current fiscal year.

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Recommended Stories

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).